WuXi PharmaTech Invests in Aldea Pharma of California

The venture capital arm of WuXi PharmaTech participated in the $24 million Series B funding of Aldea Pharmaceuticals, a California company that is developing innovative drugs to treat aldehyde metabolism disorders. The funding will underwrite a Phase II proof-of-concept trial of Aldea's lead drug candidate, AD-6626, a treatment for acute alcohol intoxication. More details... Stock Symbol: (NYSE: WX) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.